Welcome to our dedicated page for Biolargo news (Ticker: BLGO), a resource for investors and traders seeking the latest updates and insights on Biolargo stock.
BioLargo, Inc. develops and commercializes sustainable technologies across cleantech, environmental engineering, water treatment and life sciences. Company updates commonly cover its Aqueous Electrostatic Concentrator, a PFAS treatment technology designed to remove and collect per- and polyfluoroalkyl substances from liquid streams, as well as engineering services and project work in water, wastewater, remediation and minerals processing.
BioLargo news also follows subsidiary activity, including Clyra Medical Technologies and its FDA-cleared wound care products based on Copper-Iodine Complex Technology, distribution partnerships for ViaCLYR, investor communications, annual operating results, and commercialization updates across medical, environmental and battery-related business lines.
BioLargo (OTCQX:BLGO) will present at Sidoti's Micro-Cap Virtual Conference on Thursday, January 22, 2026 at 1:00 PM Eastern. BioLargo President & CEO Dennis P. Calvert will host the presentation and discuss ongoing business developments.
The event is a virtual Sidoti forum that connects small- and micro-cap issuers with investors. The live webinar requires registration at the Sidoti webinar link and provides a venue for investor Q&A and company updates.
BioLargo (OTCQX: BLGO) closed 2025 highlighting disciplined development and early-stage deployments across environmental, energy, and medical platforms. Key 2025 advances include an Aqueous Electrostatic Concentrator (AEC) install for PFAS removal at a Lake Stockholm, New Jersey municipal plant, progress toward public-private Cellinity battery factory collaborations, and Clyra Medical's first production run for ViaClyr with distributor Advanced Solution under contract.
Management expects potential meaningful commercial revenue from Clyra in 2026, continued validation from clinical KOLs, and alignment of BioLargo technologies with a large infrastructure investment cycle, while noting timing and execution remain uncertain.
BioLargo (OTCQX:BLGO) announced its subsidiary BioLargo Equipment Solutions & Technologies was featured in Chemical Engineering for its Aqueous Electrostatic Concentrator (AEC) PFAS treatment, described as producing "nearly zero waste" while removing long-, short-, and ultra-short-chain PFAS. The company also delivered an AEC system to the Lake Stockholm, New Jersey drinking water facility and is supporting provisioning, integration, and commissioning with the general contractor.
Company statements note the delivery is the final stage before the AEC goes live for the Lake Stockholm community and reference New Jersey settlements exceeding $2.5 billion that support PFAS cleanup efforts.
BioLargo (OTCQX: BLGO) will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon 21) on December 3, 2025 at 10:30 AM Eastern in Boca Raton, FL.
President & CEO Dennis P. Calvert will address prior-year financial results and ongoing business developments. The conference features formal presentations, fireside chats, one-on-one meetings and networking with hundreds of public company executives and keynote speakers.
Investors can attend the in-person session at Presentation Room 4 or learn more about the conference at nobleconference.com and company technologies at biolargo.com.
Summary not available.
BioLargo (OTCQX:BLGO) will host an investor webcast and conference call on Friday, November 14, 2025 at 1:30 PM PT / 4:30 PM ET to review results for the quarter ended September 30, 2025, discuss recent milestones, and hold a Q&A session.
Live access: register at the webcast page at least 15 minutes early. Teleconference numbers and participant code are provided for domestic and international callers. A replay is available through February 14, 2027, and the webcast replay plus presentation materials will be posted on BioLargo's Investor Relations page at www.biolargo.com/investor-relations.
BioLargo (OTCQX:BLGO) subsidiary Clyra Medical Technologies signed an exclusive stocking distribution agreement with Advanced Solution to distribute ViaCLYR™ nationwide in the United States.
ViaCLYR™ uses Clyra's proprietary Clyrasept™ copper-iodine complex, described as antimicrobial and shown to have safety, efficacy, biocompatibility, and cost-effectiveness in FDA-cleared applications. The product is scheduled for market launch in early 2026. The alliance pairs Clyra's technology with Advanced Solution's national distribution network and clinical training capabilities to accelerate adoption across healthcare providers.
Summary not available.
BioLargo (OTCQX:BLGO) announced a breakthrough upgrade to its patented Aqueous Electrostatic Concentrator (AEC) that cuts energy use by more than 90% for large-scale PFAS treatment versus prior AEC generations. The company cites prior May 2025 data showing up to 80% total life-cycle cost savings versus carbon technologies and claims non-detect PFAS removal <1 ppt in drinking and brackish water.
Example: a 1,000 gpm municipal system could see monthly energy costs fall from ~$208,000 to ~$15,700 (>$2.3M annual savings at $0.15/kWh). An industrial test showed 88% energy reduction; waste is reported as 1/40,000th that of carbon systems. A first commercial installation in New Jersey is nearing operation.
BioLargo (OTCQX: BLGO) announced that its CEO presented at the LD Micro Main Event XIX on October 20, 2025 at the Hotel del Coronado in San Diego.
The presentation covered Cellinity battery cell technology, BioLargo’s role in the global AI infrastructure investment cycle, and a general corporate update. The company filed a Form 8-K on October 20, 2025 to provide the presentation materials, which are available online at the company’s SEC filings page: https://www.biolargo.com/sec-filings.